Merck said the FDA accepted its submission of a Keytruda/chemotherapy combo drug and granted it Priority Review.
The FDA accepts Keytruda combo for review; Valeant offloads Dendreon and skincare brands; pharmacies feeling the squeeze from Express Scripts
On the heels of Keytruda’s approval in first-line lung cancer, the drugmaker kicked off an unbranded campaign raising awareness about biomarkers.
Keytruda is the first immuno-oncology drug approved to treat first-line lung cancer.
Merck launches biosimilar resource; branded insulin prices are on the rise; NICE declines to cover Opdivo
One analyst envisions how a first-line approval could set up Keytruda for success in other settings.
Critics say the direct-to-consumer ad for the immuno-oncology therapy is misleading.
Sales of Gilead’s HCV drugs fall; the DNC policy platform criticized price gouging; Janssen partners with Bristol-Myers Squibb on Opdivo combo drug
FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec
Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.
MM+M is proud to announce the fourth annual Pinnacle Awards program, which celebrates the medical marketing industry’s most venerable marketers, strategists and creators.
Get the most out of
Register for free and enjoy unlimited access to:
